- Home
- PCLA vs BLRX Comparison
PCLA vs BLRX Comparison
Compare PCLA & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCLA
- BLRX
- Stock Information
- Founded
- PCLA 2008
- BLRX 2003
- Country
- PCLA Japan
- BLRX Israel
- Employees
- PCLA N/A
- BLRX N/A
- Industry
- PCLA Building Products
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PCLA Consumer Discretionary
- BLRX Health Care
- Exchange
- PCLA Nasdaq
- BLRX Nasdaq
- Market Cap
- PCLA 18.6M
- BLRX 17.1M
- IPO Year
- PCLA 2025
- BLRX 2011
- Fundamental
- Price
- PCLA $0.44
- BLRX $4.38
- Analyst Decision
- PCLA
- BLRX Strong Buy
- Analyst Count
- PCLA 0
- BLRX 2
- Target Price
- PCLA N/A
- BLRX $19.00
- AVG Volume (30 Days)
- PCLA 170.4K
- BLRX 54.8K
- Earning Date
- PCLA 01-01-0001
- BLRX 11-24-2025
- Dividend Yield
- PCLA N/A
- BLRX N/A
- EPS Growth
- PCLA N/A
- BLRX N/A
- EPS
- PCLA N/A
- BLRX N/A
- Revenue
- PCLA $5,065,197.00
- BLRX $17,251,000.00
- Revenue This Year
- PCLA N/A
- BLRX N/A
- Revenue Next Year
- PCLA N/A
- BLRX N/A
- P/E Ratio
- PCLA N/A
- BLRX N/A
- Revenue Growth
- PCLA 5.26
- BLRX 1.19
- 52 Week Low
- PCLA $0.37
- BLRX $2.30
- 52 Week High
- PCLA $9.80
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- PCLA 41.18
- BLRX 68.39
- Support Level
- PCLA $0.44
- BLRX $3.57
- Resistance Level
- PCLA $0.48
- BLRX $4.12
- Average True Range (ATR)
- PCLA 0.02
- BLRX 0.27
- MACD
- PCLA 0.01
- BLRX 0.07
- Stochastic Oscillator
- PCLA 12.59
- BLRX 82.18
About PCLA PicoCELA Inc. American Depositary Shares
PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.